Vesalius Biocapital offers venture capital
to young European innovative life science companies
Pluriomics, an emerging Belgian/Dutch biotechnology company whose mission is to deliver cardiac drug discovery and safety solutions based on its best-in-class human iPSC-derived cardiomyocyte technology, today announced it has secured an additional €2.5M in funding. The company aims to contribute to the efficiency of the drug discovery and development process by reducing the development length, costs and late stage attrition of novel drug candidates.
The participants in this additional funding include two Belgian investors, SFPI-FPIM (The Federal Holding and Investment Company) and SambrInvest. The funds raised will be used by Pluriomics to speed up its already promising international growth, to develop the next generation cardiac safety assays and to expand capabilities in the cardiovascular drug discovery and high throughput screening domain.
Stefan Braam, CEO of Pluriomics BV, commented: “Progress at Pluriomics on both our manufacturing capabilities and drug safety and efficacy screening product and service programs has been very positive. I am delighted with the continued support from SambrInvest and our other existing investors and I am very happy to welcome SFPI-FPIM as new investor.” François Fontaine, Managing Director at SFPI-FPIM said: “Pluriomics has made tremendous and promising progress since two years. We are very pleased to join the strong syndicate of existing investors and are convinced of the added value Pluriomics will deliver in the coming years”.
For more information please contact:
+31 (0)71 332 2230
Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human induced pluripotent stem cell derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics’ Pluricyte® Cardiomyocytes and innovative technologies are exceptionally well suited for implementation in various stages of drug discovery to improve decision-making, reduce attrition rates and provide an alternative for animal testing.
Pluriomics offers unique cardiac drug discovery and safety assessment solutions based on its best-in-class human iPSC-derived cardiomyocyte cellular assays. The company aims to contribute to the efficiency of the drug discovery and development process by delivering products and services for early discovery and safety assessment.
The company is backed by private investors, Venture Funds and strategic investment from regional investment funds (Vesalius Biocapital, InnovationQuarter, S.R.I.W, SambrInvest, SFPI-FPIM). Pluriomics is based in Leiden, the Netherlands and in Gosselies, Belgium.
For more information please visit www.pluriomics.com